“Safety and Efficacy of Apremilast Through 104 Weeks in Patients swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study”, J of Skin, vol. 1, no. 3.1, p. s32, Oct. 2017, doi: 10.25251/skin.1.supp.31.